Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Jian-Ming XuJie ShenShanzhi GuYun ZhangLihua WuJian WuGuoliang ShaoYanqiao ZhangLi XuTao YinJingfeng LiuZhenggang RenJianping XiongXianhai MaoLing ZhangJiayin YangLequn LiXiaoming ChenZhiming WangKangsheng GuXi ChenZhanyu PanKuansheng MaXinmin ZhouZujiang YuEnxiao LiGuowen YinXiao ZhangShuni WangQuanren Wang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting. It might represent a novel treatment option for these patients.See related commentary by Pinato et al., p. 908.

Keyphrases

open label
end stage renal disease
chronic kidney disease
newly diagnosed
clinical trial
peritoneal dialysis
prognostic factors
randomized controlled trial
study protocol
phase ii
patient reported outcomes
smoking cessation
replacement therapy
rectal cancer